Format

Send to

Choose Destination
See comment in PubMed Commons below
Tumour Biol. 2013 Dec;34(6):3339-43. doi: 10.1007/s13277-013-0903-z. Epub 2013 Jun 8.

Clinical significance of RECK promoter methylation in pancreatic ductal adenocarcinoma.

Author information

1
Center of Organ Transplantation, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, No. 197, Ruijiner Road, Shanghai, 200025, China.

Abstract

The aim of this study was to analyze the clinical significance of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) promoter methylation in pancreatic ductal adenocarcinoma (PDA). Methylation-specific polymerase chain reaction was used to examine the promoter methylation status of RECK in 60 pairs of PDA tissue samples and adjacent non-cancerous tissue samples. Statistical analyses were applied to test the associations between RECK promoter methylation status, clinicopathologic factors, and prognosis. The rate of RECK promoter methylation was significantly higher in PDA tissues than in adjacent non-cancerous tissues (P < 0.001). RECK methylation status was significantly associated with clinical stage (P = 0.017), histological differentiation (P = 0.046), and lymph node metastasis (P = 0.003), but was not associated with gender, age, and tumor location (all P > 0.05). Additionally, RECK promoter methylation is associated with malignant behavior and poor prognosis. In conclusion, determination of RECK promoter methylation status in tumor tissues may assist in the identification of patients who require aggressive postoperative intervention in order to improve prognosis.

PMID:
23749490
DOI:
10.1007/s13277-013-0903-z
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center